Episode 5: IDH Inhibitors in AML: not so AGILE

from WolverHeme Happy Hour · host Bernard Marini, Anthony Perissinotti, et al.

In this episode, Bernie Marini and Anthony Perissinotti chat with special guest Charles Foucar, MD, a hematology specialist and expert in the field. We discuss the controversial FDA approval of ivosidenib in combination with azacitidine in newly diagnosed IDH1+ AML, based on the results of the AGILE study: https://www.nejm.org/doi/full/10.1056/NEJMoa2117344

Episode metadata supplied by the publisher feed · Published Jun 3, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Episode 5: IDH Inhibitors in AML: not so AGILE

0:00 1:24:43

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of WolverHeme Happy Hour?

This episode is 1 hour and 24 minutes long.

When was this WolverHeme Happy Hour episode published?

This episode was published on June 3, 2022.

Can I download this WolverHeme Happy Hour episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!